Learner Objectives After participating in this activity, learners should be able to: Episode Specific: Understand the components and resources of the new WA state bridge program. Assist patients with access to MOUD. Counsel patients about the effects of MOUD. Utilize harm reduction strategies in patient care. Outline the benefits of syringe services programs. Podcast Series: Increase safe opioid prescribing practices in line with HB1427. Have strategies to tailor opioid management services to their specialty and organization using evidence-based practices on appropriate prescribing and data-driven practices. Help reduce the development of tolerance to opioids. Address long-term pain management, and appropriately treat opioid addiction. Taking into account how well the learner objectives were met, how would you rate the podcast episode?1=Poor23=Good45=ExcellentPlease rate the host Nathan Schlicher, MD, JD, MBA, FACEP.1=Poor23=Good45=ExcellentContent ExpertiseCommunication SkillsPlease rate the guest speaker Liz Wolkin, MSN, RN, NPD-BC, CEN.1=Poor23=Good45=ExcellentContent ExpertiseCommunication SkillsWhat barriers are you experiencing in your practice, with respect to opioid prescribing?As a result of listening/watching, what strategies will you adapt to use in your practice? An “ineligible company,” also known as a "commercial interest," is defined as any entity producing, marketing, selling, re-selling or distributing health care goods or services consumed by, or used on, patients. Among the exemptions to this definition are government organizations, non-health care related companies and non-profit organizations that do not advocate for commercial interests. Did you perceive any bias toward a “commercial interest” in any presentation? Yes No If Yes, please explain.Do you want CME credit?(Required) Yes No
